share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Kulkarni Samarth

CRISPR Therapeutics | 4:持股变动声明-高管 Kulkarni Samarth
美股SEC公告 ·  08/12 18:46

Moomoo AI 已提取核心信息

CRISPR Therapeutics AG's CEO, Samarth Kulkarni, has completed a transaction involving the company's common stock on 08/08/2024. The action taken was classified as a bona fide gift, with Kulkarni disposing of 100,000 shares at no cost. Following this transaction, Kulkarni directly holds 222,500 shares of CRISPR Therapeutics. Additionally, Kulkarni has an indirect beneficial ownership of 85,622 shares through The Kulkarni 2023 GRAT. The transaction has been reported as completed.
CRISPR Therapeutics AG's CEO, Samarth Kulkarni, has completed a transaction involving the company's common stock on 08/08/2024. The action taken was classified as a bona fide gift, with Kulkarni disposing of 100,000 shares at no cost. Following this transaction, Kulkarni directly holds 222,500 shares of CRISPR Therapeutics. Additionally, Kulkarni has an indirect beneficial ownership of 85,622 shares through The Kulkarni 2023 GRAT. The transaction has been reported as completed.
CRISPR Therapeutics AG的CEO Samarth Kulkarni于2024年08月08日完成了一笔涉及该公司普通股的交易。此举被归类为真正的礼物,Kulkarni无偿处置了10万股。在此次交易后,Kulkarni直接持有CRISPR Therapeutics的222,500股股份。此外,Kulkarni还间接拥有The Kulkarni 2023 GRAt的85,622股份。此交易已经完成报告。
CRISPR Therapeutics AG的CEO Samarth Kulkarni于2024年08月08日完成了一笔涉及该公司普通股的交易。此举被归类为真正的礼物,Kulkarni无偿处置了10万股。在此次交易后,Kulkarni直接持有CRISPR Therapeutics的222,500股股份。此外,Kulkarni还间接拥有The Kulkarni 2023 GRAt的85,622股份。此交易已经完成报告。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息